Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal bupivacaine single-injection versus continuous ropivacaine paravertebral block after thoracoscopic lobectomy
ChiCTR2500101697Phase 4Not yet recruiting
- Sponsor
- Huadong Hospital, Fudan University
- Start
- Apr 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of liposomal bupivacaine and ropivacaine in postoperative pain (2 arms), sponsored by Huadong Hospital, Fudan University. Primary endpoint: VAS score at 48 hours postoperation. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
liposomal bupivacaineropivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on ChiCTR2500101697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101697.